Skip to content
CompletedPhase 1

Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)

NCT00895804 · University Hospital, Basel, Switzerland

Closed to entry
Status
Not accepting participants
Phase 1
Phase
16
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications. The role of beta-blockers in the treatment of cardiovascular and adverse effects of MDMA is unknown.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Effect of pindolol on subjective response to MDMA

    Measured over 24h

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 45 Years
Ages
MALE
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * Sufficient understanding of the German language * Subjects understand the procedures and the risks associated with the study * Participants must be willing to adhere to the protocol and sign the consent form * Participants must be willing to refrain from taking illicit psychoactive substances during the study. * Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids after midnight of the evening before the study session. * Participants must be willing not to drive a traffic vehicle in the evening of the study day. * Body mass index: 18-25 kg/m2 Exclusion Criteria: * Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (\>140/90 mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder. * Current or previous psychotic or affective disorder * Psychotic or affective disorder in first-degree relatives * Prior illicit drug use (except THC-containing products) more than 5 times or any time within the previous 2 months. * Participation in another clinical trial (currently or within the last 30 days) * Use of medications that are contraindicated or otherwise interfere with the effects of the study medications.

Where

1 study site

FacilityCityRegionCountry
Heffter Research Center, University Hospital of PsychiatryZurichCanton of ZurichSwitzerland

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT00895804 on ClinicalTrials.gov →

Last updated in the registry 2009-06-15. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits